Phio reports Q2 2026 results, sets Q3 FDA meeting on PH-762 path
Phio said its Phase 1b skin cancer trial finished in March 2026, with final documentation still in preparation as it plans an FDA meeting in the third quarter.
Phio Pharmaceuticals Corp. reported second quarter 2026 financial results and a business update on August 6, 2026, covering its lead candidate PH-762, an INTASYL siRNA compound. Phio's lead clinical development program is an INTASYL compound, PH-762, that silences the PD-1 gene implicated in various forms of skin cancer.1
The company's Phase 1b trial, a U.S. multi-center dose-escalating study of intratumoral PH-762 in patients with cutaneous squamous cell carcinoma, melanoma and Merkel cell carcinoma, was designed to evaluate safety and tolerability of neoadjuvant use, assess tumor response, and determine dose or dose range for continued study.1 The study enrolled 22 patients, including 20 with cutaneous squamous cell carcinoma, one with melanoma and one with Merkel cell carcinoma, and was completed in March of this year.1 As of the report date, final comprehensive clinical study documentation is in final preparation stage, which will be submitted to the FDA.1 Phio intends to request an FDA meeting in the third quarter of 2026 to discuss next steps in the clinical trial design and development strategy for PH-762.1
On the manufacturing and regulatory side, CEO Robert Bitterman said the company advanced foundational building blocks for the PH-762 program in the second quarter, including commencement of commercial scale API and dosing of a long term non-clinical study, both expected to be completed by year end, alongside final analysis of pharmacology outcomes from the Phase 1b trial.1
On financing, in April 2026 the company established an at-the-market equity offering program through H.C. Wainwright & Co., LLC, allowing sale of common stock with an aggregate sales price of up to $6.36 million.1
On cash, Phio had cash and cash equivalents of $13.0 million as of June 30, 2026, compared with $21.0 million at December 31, 2025.1 The company said it expects existing cash to fund planned operations into the second half of 2027.1 Net loss was $4.1 million for the quarter, compared with $2.2 million a year earlier.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.